Resultado de búsqueda
BioNTech’s portfolio contains more than 25 product candidates in clinical trials. In pursuit of changing the treatment paradigm with individualized cancer therapies, our pipeline encompasses oncology product candidates including individualized and off-the-shelf mRNA-based therapies , innovative chimeric antigen receptor T cells , bispecific checkpoint immunomodulators , targeted cancer ...
Welcome to our investor page. Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of ...
BioNTech SE | 238,274 followers on LinkedIn. Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. | At BioNTech we understand ...
At a glance: Our iNeST Platform. Concept : Individualized mRNA cancer vaccine encoding for an individually selected number of patient-specific tumor neoantigens aiming to induce a potent and precise immune response against the patient’s unique tumor. mRNA Format: Optimized uridine mRNA (uRNA) for improved vaccine efficacy.
22 de abr. de 2024 · BioNTech disavows any obligation to update the information contained in such press releases after the date of their issuance. BioNTech SE. An der Goldgrube 12. 55131 Mainz, Germany. T: +49 6131 9084-0. F: +49 6131 9084-2121. service@biontech.de. Company.
23 de may. de 2024 · Todas las noticias sobre BioNTech publicadas en EL PAÍS. Información, novedades y última hora sobre BioNTech.
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
